ID   H209/CP
AC   CVCL_9V41
DR   cancercelllines; CVCL_9V41
DR   Wikidata; Q54872011
RX   PubMed=8646677;
CC   Population: Caucasian.
CC   Selected for resistance to: ChEBI; CHEBI:27899; Cisplatin (CDDP).
CC   Sequence variation: Mutation; HGNC; 9884; RB1; Simple; p.Cys706Phe (c.2117G>T); ClinVar=VCV000376330; Zygosity=Homozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; c.673-2A>T (IVS6-2A>T); ClinVar=VCV000635388; Zygosity=Homozygous (from parent cell line).
CC   Derived from site: Metastatic; Bone marrow; UBERON=UBERON_0002371.
DI   NCIt; C4917; Lung small cell carcinoma
DI   ORDO; Orphanet_70573; Small cell lung cancer
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_1525 ! NCI-H209
SX   Male
AG   55Y
CA   Cancer cell line
DT   Created: 23-02-16; Last updated: 05-10-23; Version: 10
//
RX   PubMed=8646677; DOI=10.1002/(SICI)1097-0142(19960501)77:9<1797::AID-CNCR7>3.0.CO;2-9;
RA   Jain N., Lam Y.-M., Pym J., Campling B.G.;
RT   "Mechanisms of resistance of human small cell lung cancer lines
RT   selected in VP-16 and cisplatin.";
RL   Cancer 77:1797-1808(1996).
//